Abstract 329P
Background
Recent studies showed that stimulation of HDACs could induce PD-1 dynamic expression on DCs, macrophages, colonic stromal cells, and cancer cells. Surprisingly, it is little is known about the specific expression of important HDAC10 in NSCLC tissue. In this study, we evaluated the expression level of HDAC10 and the correlation of HDAC10 and PD-L1 in NSCLC tissues and analyzed the predicting role of HDAC10 in cancer cells on postoperative survival in NSCLC patients receiving pulmonary lobectomy.
Methods
A total of 180 NSCLC patients receiving complete pulmonary resection and systematic lymph node dissection between April 2004 and August 2009 were enrolled. All the patients had integrated clinicopathological records and follow-up data. HDAC10 and PD-L1 expression on NSCLC samples were determined by using immunohistochemistry.
Results
Our results showed that HDAC10 expression level in cancer tissue was significantly higher than that in para-cancer tissue. HDAC10 expression level was also positively correlated with the PD-L1 expression level (r = 0.213, P < 0.05). Multivariate analysis showed that expression level of HDAC10 was an independent prognostic factor and HDAC10 overexpression indicated a poor overall survival in pulmonary carcinoma (r = 0.540, P < 0.001).
Conclusions
To our knowledge, this is the first time to associate HDAC10 with lung cancer patients’ survival status and to explore correlation between HDAC10 and PD-L1 expression. Our findings indicated that HDAC10 could be a valuable predicting marker that might provide help for clinicians to design effective therapeutic modality against NSCLC. Treatment response might be especially prominent in patients overexpressing HDAC10 in cancer cells. Our study suggest clinical relevance for the immune effects of HDAC10 and provide a rationale for the clinical evaluation of PD-L1 blockade in combination with HDAC10 inhibition.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Jinzhou Medical University.
Funding
This study was supported by the CSCO-HANSOH PHARMA Science Foundation of China (number Y-HS2019-29).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract